Haozhen Q. Ren

Zhongshan Road 321
Nanjing, 210008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Emerging nanomedicine for liver diseases treatment.

Emerging nanomedicine for liver diseases treatment.

Journal: Journal of nanobiotechnology

Published: September 01, 2025

Developing mRNA Nanomedicines with Advanced Targeting Functions.

Developing mRNA Nanomedicines with Advanced Targeting Functions.

Journal: Nano-micro letters

Published: November 12, 2024

Correlation between the mutation spectrum of the UGT1A1 gene and clinical phenotype in patients with inherited hyperunconjugated bilirubinemia

Correlation between the mutation spectrum of the UGT1A1 gene and clinical phenotype in patients with inherited hyperunconjugated bilirubinemia

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: May 11, 2024

Hepatocellular carcinoma biomarkers screening based on hydrogel photonic barcodes with tyramine deposition amplified ELISA.

Hepatocellular carcinoma biomarkers screening based on hydrogel photonic barcodes with tyramine deposition amplified ELISA.

Journal: Biosensors & bioelectronics

Published: January 11, 2024

Hierarchical mesoporous silicon and albumin composite microparticles delivering DOX and FU for liver cancer treatment.

Hierarchical mesoporous silicon and albumin composite microparticles delivering DOX and FU for liver cancer treatment.

Journal: International journal of biological macromolecules

Published: January 04, 2024

Correction: Mesenchymal stem cell-secreted prostaglandin E2 ameliorates acute liver failure via attenuation of cell death and regulation of macrophage polarization.

Correction: Mesenchymal stem cell-secreted prostaglandin E2 ameliorates acute liver failure via attenuation of cell death and regulation of macrophage polarization.

Journal: Stem cell research & therapy

Published: November 24, 2023

CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma.

CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma.

Journal: Cell death discovery

Published: August 16, 2023

Engineered stem cells by emerging biomedical stratagems.

Engineered stem cells by emerging biomedical stratagems.

Journal: Science bulletin

Published: July 10, 2023

Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells.

Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells.

Journal: Stem cell research & therapy

Published: April 03, 2023

Pharmacist-Driven Dosing Services and Pharmaceutical Care Increase Probability of Teicoplanin Target Concentration Attainment and Improve Clinical and Economic Outcomes in Non-Critically Ill Patients.

Pharmacist-Driven Dosing Services and Pharmaceutical Care Increase Probability of Teicoplanin Target Concentration Attainment and Improve Clinical and Economic Outcomes in Non-Critically Ill Patients.

Journal: Infectious diseases and therapy

Published: March 13, 2023

TP53 mutation-related senescence is an indicator of hepatocellular carcinoma patient outcomes from multiomics profiles.

TP53 mutation-related senescence is an indicator of hepatocellular carcinoma patient outcomes from multiomics profiles.

Journal: Smart medicine

Published: February 09, 2023

Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy.

Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy.

Journal: Nano-micro letters

Published: December 08, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026